KERATIN 17 AND A2ML1 ARE NEGATIVE PROGNOSTIC BIOMARKERS IN NON-SMALL CELL LUNG CANCER
Babu S, Horowitz M, Delgado-Coka L, Roa-Peña L, Akalin A, Escobar-Hoyos L, Shroyer K. KERATIN 17 AND A2ML1 ARE NEGATIVE PROGNOSTIC BIOMARKERS IN NON-SMALL CELL LUNG CANCER. Pathology - Research And Practice 2024, 155643. DOI: 10.1016/j.prp.2024.155643.Peer-Reviewed Original ResearchNon-small cell lung cancerLung squamous cell carcinomaNegative prognostic biomarkerCell lung cancerSquamous cell carcinomaPancreatic ductal adenocarcinomaPrognostic biomarkerCell carcinomaMultiplex immunohistochemistryPrognostic accuracyDuctal adenocarcinomaLung cancerPrimary lung squamous cell carcinomaHead and neck squamous cell carcinomaNeck squamous cell carcinomaImpact treatment decisionsClinicopathological factorsClinicopathological variablesOverall prognosisPulmonary adenocarcinomaSolid tumorsNon-smallSurvival differencesPrognostic dataCo-testingKeratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Delgado-Coka L, Roa-Peña L, Babu S, Horowitz M, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Akalin A, Jiang W, Larson B, Hendifar A, Picozzi V, Choi M, Shroyer K, Escobar-Hoyos L. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal Of Clinical Pathology 2024, 162: 314-326. PMID: 38642081, PMCID: PMC11369068, DOI: 10.1093/ajcp/aqae038.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPredictive biomarkersDuctal adenocarcinomaK17 expressionKeratin 17Gemcitabine-based therapyGemcitabine-based chemotherapyBasal molecular subtypeTumor mutation statusResponse to chemotherapyPancreatic ductal adenocarcinoma cellsThreshold of expressionChemotherapeutic regimensAdvanced-stageClinicopathological variablesMutation statusPrognostic stratificationMolecular subtypesShorter survivalLonger survivalFormalin-fixedImmunohistochemical testsPredictive valuePatientsTherapeutic interventions